IDSA: Antibiotics for Seven Days Feasible for Patients Hospitalized With Bloodstream Infections
MONDAY, Oct. 21, 2024 -- Treating hospitalized patients with bloodstream infections with antibiotics for seven days is noninferior to treating for 14 days, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 16 to 19 in Los Angeles.
Nick Daneman, M.D., and Rob Fowler, M.D., from the University of Toronto, and colleagues randomly assigned 3,608 hospitalized patients (ward and intensive care unit [ICU]) with bloodstream infections to receive seven- or 14-day (1,814 and 1,794 patients, respectively) antibiotic treatment.
The researchers reported that most infections were community-onset (75.4 percent), followed by hospital-acquired (13.4 percent) and ICU-acquired (11.2 percent). The urinary tract (42.2 percent), abdomen (18.8 percent), lung (13.0 percent), vascular catheters (6.3 percent), and skin or soft tissue (5.2 percent) were the most common bacteremia sources. Ninety-day mortality occurred in 14.5 percent of patients receiving seven-day and in 16.1 percent of patients receiving 14-day treatment, demonstrating noninferiority of shorter duration treatment. Noninferiority was confirmed in a per-protocol analysis (−2.0 percent; 95 percent confidence interval, −4.5 to 0.6). Findings were similar across secondary clinical outcomes and prespecified patient, pathogen, and syndrome subgroups.
"Finding strong evidence that supports shorter antibiotic treatment durations is a top priority to advance antimicrobial stewardship as drug-resistant bacteria are increasingly becoming a public health threat," Daneman said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Antibiotics in Pregnancy, Infancy Not Linked to Autoimmune Diseases
TUESDAY, Aug. 26, 2025 -- There seems to be no association between antibiotic exposure during the prenatal period or early infancy and development of autoimmune diseases in...
Dalbavancin Noninferior to Standard Therapy for Complicated S. Aureus Bacteremia
FRIDAY, Aug. 15, 2025 -- Dalbavancin is not superior to standard therapy for adults with complicated Staphylococcus aureus bacteremia, but clinical efficacy met the criteria for...
More Than 110,000 Rich's Ice Cream Bars Recalled Due to Listeria Risk
WEDNESDAY, July 23, 2025 — More than 100,000 Rich's Ice Cream Co. bars have been recalled due to possible listeria contamination. The affected ice cream bars were sold...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.